INTRODUCTION
Asthma is a heterogeneous disease that is usually characterized by chronic airway inflammation. Its pathophysiology involves cells and inflammation mediators, and a genetic predisposition influenced by environmental interaction mediators and cells.
Asthmatics have a history of respiratory symptoms such as wheezing, shortness of breath, chest tightness, and coughing that vary over time and in intensity, together with variable expiratory airflow limitation [1, 2] .
Of the various chronic respiratory diseases, asthma is among those that has the greatest impact on public health [3] . Its average prevalence in Spain is 5.7% [3] , but depending on the geographical area it can reach more than 10% [4] . With a mortality rate of 2.22 per 100,000 inhabitants in 2005, it leads to high consumption of health and non-health resources. Its estimated annual cost to Spain is 1480 million euros, with the associated pharmacological treatment representing around 33% of that figure [5] .
The main goals of asthma treatment are to control symptoms such as daytime symptoms, sleeping difficulties, and activity limitations, and to reduce the future risk of adverse outcomes such as fixed airflow limitation, medication side effects, and exacerbations that are independent of symptom control. Low-to-high inhaled doses of a combination of inhaled corticosteroids (ICS) and a long-acting b2-agonist (LABA) represent the first-choice maintenance treatment recommended by Spanish and international guidelines for patients with moderate-to-severe persistent asthma [1] .
Adult 
METHODS

Study Design
Based on the work of Price et al. [9] , we developed a Markov model that was adapted to the new GEMA (Spanish Guidelines for Asthma Management 2015) and GINA (Global Initiative for Asthma: Management and Prevention Strategy) [1, 2] guidelines, which considered five asthma health states: optimal control, suboptimal control, outpatient-managed exacerbation, inpatient-managed exacerbation, and death (Fig 1) .
Asthma control classification was based on daily symptoms, night-time waking due to asthma, need for reliever medication, and activity limitation. According to the GINA 2015 criteria (Table 1) , well-controlled patients represent the state of successful control (SC), and partly controlled and uncontrolled patients correspond to the suboptimal control state (SOC).
Depending on its/their severity, worsening asthma and exacerbations can be self-managed, treated in the primary care center, or will require emergency department care with or without hospital admission. In our model, self-management corresponded to SC and SOC, the need for primary care and emergency department care corresponded to outpatient managed exacerbation (OME), and the need for hospitalization corresponded to inpatient managed exacerbation (IME) [1] .
The death state includes deaths from all causes: asthma-related and non-asthma-related. The time horizon was set at 12 months, and we used weekly probability transitions. Noninferiority was tested using a covariance analysis with a 95% CI C -0.2 L for the lower limit. The main results are presented in Table 2 [10].
A randomized double-blind multi-country study of asthmatic patients using FP/FORM or BF was performed in which the primary endpoint was the change in FEV1 from pre-dose at baseline to pre-dose at week 12 and the secondary endpoints were the mean change in FEV 1 from pre-dose at baseline to 2 h post-dose at week 12 and the number of discontinuations due to lack of treatment efficacy. This study demonstrated that FP/ FORM and BF present comparable efficacies in terms of primary and secondary endpoints. The In the past 4 weeks, has the patient:
Well-controlled Partly controlled
Uncontrolled
Had daytime asthma symptoms more than twice/week? None of these 1-2 of these 3-4 of these Woken at night due to asthma?
Required reliever medication for symptoms more than twice a week?
Experienced any activity limitation?
predefined noninferiority baseline limit for the primary endpoint was established at -0.2 L (95% CI -0.130, 0.043 L; p\0.01), and the results obtained are shown in Table 3 [11].
We adopted the same transition probabilities for the three options and incorporated FS values from the Gerzeli 2012 study, in which calculations were performed using the raw data from the ICAT SY trial (Inhaled Combination Asthma Treatment versus SYmbicort) [12] . The initial proportions of the patients in the SC and SOC states was taken from Demoli 2010: 53% and 47%, respectively.
Weekly health utility weights were also derived from the mean utility values obtained in the Gerzeli 2012 study [8, 13] (Table 4) .
Cost Estimation
The main economic analysis was conducted from a societal perspective (the direct healthcare cost, direct non-healthcare cost, and indirect cost were included). An expert panel composed of two allergists and two pneumologists from different hospitals and regions of Spain were recruited to validate the the corresponding values are 250-500 mcg and [500 mcg for propionate fluticasone. Table 5 shows the average (range), the unitary cost, and the average weekly cost (range) of maintenance treatment for each drug combination and state considered in the model.
The cost of home rescue medication (OME), associated with SC and SOC, includes (Table 6 ).
Other pharma costs not related to home rescue medication include those of the adrenergic inhaler, other COPD drugs, anticholinergics, and systemic corticosteroids. The data used to estimate this cost were derived from the EPAR (doses), from Idoctus [15] (unitary cost), and from Collados et al. [16] (the percentage of patients treated with them); see Table 7 .
Direct non-pharma healthcare costs were assessed by calculating the average weighted populations of the different Spanish regions, available published prices, and the expert panel's consumption data. Table 8 shows the Table 9 .
Base Case Analyses
This analysis assumed that 53% of the patients were initially defined as SC and 47% were initially defined as SOC [8] , that there were 1.23 and 5.33 weekly home management exacerbations, respectively, for SC and SOC patients, that there was a ratio of women to men of 1:1, and that the patients had a mean age of 55 years, according to the expert panel.
Effectiveness was expressed as quality-adjusted life years (QALYs) gained, and the results were assessed based on the incremental cost-effectiveness ratio (ICER).
Deterministic and Probabilistic Sensitivity Analyses
Uncertainty from the social and payer perspective was tested using univariate (OWSA) and probabilistic (PSA) sensitivity analyses to ensure the strength of the model. BF budesonide/formoterol, FP/FORM fluticasone propionate/formoterol, FS fluticasone propionate/ salmeterol, SC successful control, SOC suboptimal control, OME outpatient-managed exacerbation, IME inpatient-managed exacerbation, D death
The OWSA was developed by increasing and decreasing the deterministic value by 10% or by using the IC limits when they were available.
The results of the PSA were expressed graphically by plotting a ''cloud'' of iterations on a cost-effectiveness plane.
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RESULTS
Base Case Analysis
In the base case analysis, FP/FORM proved to be less expensive than BF or FS (by 2.8% and 1.1%, respectively; see Table 10 ). This advantage was due to a cost reduction associated with the successful control of patients, as the costs relating to emergency and impatient exacerbations were quite similar for all drug combinations. The reason for this was that the cost of acquiring FP/FORM was 24% lower than that of FS and 32% lower than that of BF.
The suboptimal control health state dominated (was 80% of) the overall cost in all of the options and scenarios analyzed. SC successful control, SOC suboptimal control, OME outpatient-managed exacerbation, IME inpatient-managed exacerbation, C complications
The QALYs of the three options were very similar, as there were minimal differences in efficacy between the strategies.
Univariate Sensitivity Analysis
The results of the univariate sensitivity analysis did not show any change from the base case results. Only costs relating to SC and SOC showed any changes, but FP/FORM was always found to be the most favorable option.
Probabilistic Results
When the PSA was run, results confirmed the data obtained from the base case scenario, which indicated that FP/FORM was the most economically attractive option (Table 11) . Total costs and total QALYs were expressed graphically to highlight differences in the ICER among iterations. Looking at the two probabilistic cost-effectiveness planes (Fig. 2a,   b ), it is apparent that the two ''clouds'' of points (where a cloud represents iterations for a particular drug combination) almost fully overlap with each other in each plot, reflecting the numerical results shown in Table 11 .
DISCUSSION
Cost-effectiveness evaluation is a tool used for health technology assessment as a means to support universal coverage. In Spain, the Due to a lack of data on the comparative efficacies of different types of devices for administering the drugs considered here, we have not considered the potential benefits and disadvantages of those different devices, but this issue should be explored in future trials assessing the efficacy and benefits of these drug combinations for patients.
The main limitation of the study was the use of the same transition probabilities and utilities for the different treatments because patient-level data were not available and the clinical trials were not designed to evaluate them.
Although FP/FORM has a more rapid onset of action, and this could not be modeled properly, FP/FORM seems to be the appropriate option for patients with moderate-to-severe asthma, as it is the least expensive option but is as effective as the other two options. Formoterol is a rapid and long-acting b2-agonist that has demonstrated a faster onset of action than salmeterol in patients with moderate-to-severe asthma in clinical trials [20] [21] [22] . This may increase the patient's quality of life, with treatment adherence being reflected in better disease control. However, in this work, we used data from clinical trials where the rapid onset of FP/ FORM-which reflects the faster bronchodilatory effects of formoterol compared with salmeterol-was not considered as an effectiveness outcome that could represent another advantage of FP/FORM aside from its lower acquisition cost. 
